

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 May 2001 (03.05.2001)

PCT

(10) International Publication Number
WO 01/30351 A1

(51) International Patent Classification⁷: **A61K 31/47**, 9/48

JAMES, Christopher [GB/IT]; Viale Sempione, 19,
I-20020 Arese (IT).

(21) International Application Number: PCT/EP00/09647

(22) International Filing Date: 2 October 2000 (02.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(30) Priority Data:
9925127.4 22 October 1999 (22.10.1999) GB

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **PHARMACIA & UPJOHNS.P.A.** [IT/IT]; Via Robert Koch, 1, 2, I-20152 Milano (IT).

Published:

— With international search report.

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **MUGGETTI, Lorena** [IT/IT]; Via Trento, 38, I-20035 Meda (IT). **MARTINI, Alessandro** [IT/IT]; Via Desiderio da Setignano, 14, I-20100 Milano (IT). **CIVAROLI, Paola** [IT/IT]; Via Giuseppe Frua, 20, I-20100 Milano (IT).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/30351 A1

(54) Title: ORAL FORMULATIONS FOR ANTI-TUMOR COMPOUNDS

(57) Abstract: The present invention relates to a semi-solid filling medium which comprises a camptothecin derivative; a pharmaceutically acceptable carrier matrix which is a polyglycolized glyceride; and an effective thickening-reducing and stabilising-promoting amount of one or more pharmaceutically acceptable excipients.

Title: Oral formulations for anti-tumor compounds

5

FIELD OF THE INVENTION

The present invention provides an oral dosage form for camptothecin derivatives, such as, for example, irinotecan (7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy camptothecin or its pharmaceutically acceptable salts, especially hydrochloride (CPT-11); or topotecan (9-dimethylaminomethyl-10-hydroxy-camptothecin) or its pharmaceutically acceptable salts, especially hydrochloride.

10

BACKGROUND OF THE INVENTION

Camptothecins are a new class of cytotoxic agents, which have been undergoing both preclinical and clinical testing against various solid tumors. The nuclear enzyme topoisomerase I (Topo I), along with the other topoisomerases, functions to resolve topological problems during DNA replication. These enzymes are the target for camptothecin and its derivatives. These agents are derivatives of an extract from the Chinese tree *Camptotheca acuminata*, and were originally shown to be active against L1210 murine leukemia (Wall, M.E., Wani, M.C., CoY, C.E., Palmer, K.H., MCP hail, A.T. and Sim, G.A.: Plant antitumor agents. 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from *Camptotheca acuminata*, J. Chem. Soc., 88:3888, 1966). Further study confirmed that alkaline labile DNA (single strand) breaks were formed when camptothecin was added to cells in tissue culture and that the breaks rapidly resealed after removal of the drug. These DNA single strand breaks represent the nicks that form when camptothecin stabilizes the covalent adducts between genomic DNA and the reparative

15

20

25

30

nuclear enzyme topo I (Horwitz, S.B., Chang, C.S.C.K. and Grollman, A.P.: Studies on camptothecin. 1. Effects on nucleic acid and protein synthesis. Mol. Pharmacol, 7:632,1971; Hsiang, Y.H. and Liu, L.F: Identification of
5 mammalian DNA topoisomerase I as an intracellular target of the anticancer drug Camptothecin. Cancer Res., 48: 1722, 1988). Early studies also showed maximal S-phase toxicity, and that the topo I-associated DNA single strand nicks led to the formation of more persistent double strand breaks
10 which ultimately resulted in cell death. Camptothecins also appear to have other cytotoxic effects which amount for their activity in human tumor xenografts that typically have low S-phase fractions, though these effects are to be clearly defined.

15 A number of more soluble and less toxic analog of camptothecin have been developed, among them CPT-11 and topotecan hydrochloride are commercial products.

Topotecan hydrochloride is indicated for the treatment of metastatic carcinoma of the ovary after failure of initial
20 or subsequent chemotherapy and for the treatment of small cell lung cancer sensitive disease after failure of first-line chemotherapy.

CPT-11 has been studied extensively in both preclinical and clinical trials and has shown good anti-tumor activity
25 against a broad spectrum of experimental tumor models (Kunimoto, T., Nitta, K., Tanaka, T. Uchara, N., Baga, H., Takeuchi, M., Yokokura, T., Sawada, S., Miyasaka, T. and Mutai, M.: Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, against
30 murine tumors. Cancer Res., 47:5944, 1987). It has recently received FDA approval for the treatment of colon cancer.

Developed in 1983, CPT-11 is a semi-synthetic derivative of camptothecin which is, in effect, a prodrug converted to 7-

ethyl-10-hydroxy-camptothecin (SN-38), following hydrolysis in the liver.

The intravenous drug form of CPT-11 is being developed for the treatment of colorectal cancer.

5 It is well known that parenteral administration of antitumor drugs such as, for example, camptothecin derivatives, is associated with some intrinsic disadvantages and drawbacks, e.g., patient discomfort or the requirement for the patient to travel to the physician's office for drug administration,
10 with obvious results in patient inconvenience.

Thus the need has arisen to develop oral formulations of anti-tumor drugs that would allow to overcome the inconvenience and the discomfort of the patient that are associated with the parenteral way of administration.

15 Classical oral formulations are, for example, solid oral dosage forms, that are medication delivery systems presented as solid dose units readily administered by mouth. The group includes tablets, capsules, cachets and pills, as well as bulk or unit-dose powders and granules. The group
20 constitutes the most popular form of presentation, and tablets and capsules account for the greatest number of preparations in this category.

It has long been known in the pharmaceutical industries that capsules are a convenient form for the oral administration
25 of a variety of active agents because of their relative ease of manufacture (compared with other dosage forms such as tablets), flexibility of size and dose. Capsules have traditionally been used for powder or granule formulations but, in recent years, capsules have been adapted to contain
30 the active ingredient in the form of paste, semi-solid or liquid formulation.

Since, for example, CPT-11 and topotecan hydrochloride are classified as class I cytotoxic agents, any form of leakage from the dosage form would present a safety concern.

The risk of leakage of a cytotoxic agent from a formulation as a tablet or powder-filled capsule, both during manufacturing and distribution, is extremely high.

Thus, in light of the above mentioned problem about the safe handling of these drugs, it is desirable to formulate them in a filling medium which is semi-solid and can be readily introduced and maintained into capsules without the expected problem of leakage.

In particular, a thermoplastic hot-melt type capsule formulation can be suitable for enhancing stability and for minimizing leakage concerns.

A problem to be solved when manufacturing a capsule filled with a semi-solid matrix, especially when it comprises a high concentration of an active such as a camptothecin derivative in the formulation, is the thickening, i.e. the increase of semi-solid matrix viscosity over time. The thickening of the semi-solid mass has repercussions not only on the manufacturing of the formulation (e.g. non-homogeneity of the formulation and impossibility to partition the formulation into capsules), but also on the reproducibility of the release profile of the active ingredient from the formulation itself.

A further problem to be faced regards the chemical and physical stability of the semi-solid filling matrix with aging. Several examples are described in the scientific literature, where semi-solid matrix systems change their physical state and their pharmaceutical characteristics with time and storage in different humidity/temperature conditions. As examples, SanVicente et al. clearly shows that the dissolution rate from glyceride matrices decreases

with time (Proceedings of the 2nd World Meeting APGI/APV, Paris May 25-28, 1998, p.261-2); and Sutananta W. et al. clearly shows the effect of aging on the physical properties of similar matrices, explored by DSC and tensile strength measurements (International Journal of Pharmaceutics, 111 (1994) 51-62).

Both the above mentioned problems were experienced when formulation activities for manufacturing a semi-solid matrix formulation for a camptothecin derivative were performed, especially when a semi-solid matrix comprises high concentrations of said camptothecin derivative.

There is therefore a need to find a formulation approach which allows to overcome thickening problems and to secure the maintenance of the physico-chemical characteristics of the semi-solid filling medium during manufacturing and storage.

It has now been surprisingly found that, by adding an effective amount of one or more excipients chosen from: a lecithin, a phospholipid, a pharmaceutical acceptable oil, a polyethyleneglycol, and a saturated or unsaturated mono-, di- or triglyceride to the carrier matrix in which the camptothecin derivative is dispersed or dissolved, the above-mentioned problems can be solved.

25 DESCRIPTION OF THE INVENTION

Accordingly, the present invention provides a pharmaceutical composition suitable for oral administration which comprises a camptothecin derivative, a pharmaceutically acceptable carrier matrix which is a polyglycolized glyceride, and at least one pharmaceutically acceptable excipient chosen from a lecithin, a phospholipid, a pharmaceutically acceptable oil, a polyethyleneglycol, and a saturated or unsaturated mono-, di- or triglyceride.

The said pharmaceutically acceptable excipient is typically contained in the composition of the invention in an amount effective to reduce thickening and promote stabilisation of the combination of the camptothecin derivative and the carrier matrix.

The pharmaceutical composition of the invention has a semi-solid consistency and can therefore conveniently be used as a filling inside a capsule for oral administration. The composition is accordingly hereafter also referred to as a semi-solid filling medium.

Preferably, the excipient used in the composition of the invention is a lecithin selected from different types of commercially available lecithins.

The use of a compound chosen from a lecithin, a phospholipid, a pharmaceutically acceptable oil, a polyethyleneglycol and a saturated or unsaturated mono-, di- or triglyceride as an excipient in the composition of the invention has the effect of reducing thickening and promoting stability of the carrier matrix in which the camptothecin derivative is dispersed or dissolved.

The present invention provides a first process for producing a pharmaceutical composition of the invention as defined above, which process comprises adding an effective amount of the or each said pharmaceutically acceptable excipient to a solution or dispersion of a camptothecin derivative in the polyglycolised glyceride. In addition the invention provides a second process for producing a pharmaceutical composition of the invention as defined above, which process comprises dissolving or dispersing a camptothecin derivative in a molten homogenous mixture of the polyglycolized glyceride and the or each said pharmaceutically acceptable excipient. In both process embodiments the resulting

composition is stabilised and has controlled viscosity owing to the presence of the excipients.

The present invention also provides an oral formulation which comprises a capsule shell and, as a filling, a pharmaceutical composition as defined above. This oral
5 formulation may take the form of a capsule. In one aspect of the invention the oral formulation is for use in the treatment of a human cancer.

The present invention is particularly advantageous for the
10 production of oral solid dosage forms which can be prepared by filling capsules with the pharmaceutical composition (semi-solid medium) of the invention, using standard techniques. A capsule consisting of a capsule shell and capsule filling, wherein the filling comprises a
15 pharmaceutical composition of the invention as described above, is also an object of the present invention.

Examples of the camptothecin derivative which is used in the present invention include irinotecan and its pharmaceutically acceptable salts, in particular the
20 hydrochloride (CPT-11), topotecan and its pharmaceutically acceptable salts, in particular hydrochloride, SN-22, SN-38, 9-amino-20(S)-CPT, 9-nitro-20(S)-CPT (rubitecan); preferably it is CPT-11 or topotecan hydrochloride; more preferably it is CPT-11.

25 Camptothecin derivatives described in the US patent No. 5,843,954, in the name of Kabushik Kaisha Yakult Honsha and Daiichi Pharm. Co, Ltd, may also be used in the present invention.

According to the present invention, the amount of
30 camptothecin derivative per unit dose is in the range of from about 1 mg to about 100 mg, preferably from about 5 mg to about 100 mg.

The carrier matrix used in the composition of the invention is a polyglycolyzed glyceride. Polyglycolyzed glycerides which can be used in the present invention are generally mixtures of known monoesters, diesters and triesters of glycerols and known monoesters and diesters of polyethylene glycols with a mean relative molecular mass between about 200 and 6000. They may be obtained by partial transesterification of triglycerides with polyethylene glycol or by esterification of glycerol and polyethylene glycol with fatty acids using known reactions. Preferably, the fatty acid contains 8-22 carbon atoms, particularly 8-18 carbon atoms. Examples of natural vegetable oils, which may be used, include palm kernel oil and palm oil. However, these are only examples. The polyol suitably has a molecular weight in the range of about 200-6000 and preferably contains polyethylene glycols, although other polyols may be employed, such as, for instance, polyglycerols and sorbitol. They are known under the trademark Gelucire® and are commercially available from Gattefossé s.a., Saint Priest, France.

Further, two or more polyglycolyzed glycerides may be mixed in order to adjust both the Hydrophilic-Lipophilic Balance (HLB) value and the melting point to a desired value. The HLB value and melting point of the composition may further be adjusted with the addition of components such as polyethylene glycols, polyethylene glycol fatty acid esters and fatty acid alcohols. According to the present invention, it is well within the skill of the artisan to mix the polyglycolysed glycerides to obtain desired HBL values and melting points.

HLB (Hydrophilic-Lipophilic Balance) scale is a numerical scale, extending from 0 to 14, where lower numbers denote more lipophilic and hydrophobic substances and higher

numbers denote more hydrophilic and lipophobic substances. The wide range of available polyglycolyzed glycerides allows the selection of the proper matrix according to the processing and release requirements of the formulation. For example, it is possible to achieve either prompt or sustained drug release depending on the thermal and HLB nature of the polyglycolyzed glyceride used as the matrix. According to the present invention, the amount of the carrier matrix is in the range of from about 70% to about 99.9% (w/w), preferably from about 80% to about 95% (w/w) of the pharmaceutical composition.

In particular, the saturated polyglycolyzed glyceride known under the trade name Gelucire® 44/14 is used, as a carrier matrix, according to the present invention.

When a camptothecin derivative such as, e.g. CPT-11, is dispersed or dissolved in the molten polyglycolyzed glyceride mass, a thickening phenomenon (increase in viscosity over time) has been experienced. In this case, thickening made capsule filling process very difficult after a few hours from the beginning of the capsule preparation process arising severe concerns on the development of such formulations. This problem is typically encountered and put in evidence when, in particular, high concentrations of the camptothecin derivative such as, e.g., CPT-11 or topotecan hydrochloride, are dispersed or dissolved in a polyglycolyzed glyceride. In fact, particularly when the active drug substance represents a significant amount of the semi-solid mass, this can have a deep influence on the physical behavior of the matrix.

Furthermore, although described as largely chemically inert materials with good long-term stability, it is reported in the literature that polyglycolyzed glycerides may exhibit aging effects. This phenomenon can result in a change of the

physical properties of the matrix, largely influencing the reproducibility of the drug release profile during storage.

In summary, not only manufacturing problems, but also instability problems are to be faced by a skilled artisan.

5 The present inventors have thus carried out an extensive investigation. As a result, it has been found that one or more suitable excipients, capable of reducing thickening and promoting the stability (i.e. securing the maintenance) of the physico-chemical characteristics of the semi-solid
10 filling medium during manufacturing and storage, can be chosen among the chemical classes of: lecithins; phospholipids; pharmaceutical acceptable oils, e.g. soybean oils and the like, polyethylenglycols and saturated or unsaturated mono-, di- or triglycerides. A preferred
15 excipient is a lecithin selected from the different types of lecithins commercially available, in particular the lecithin known under the trade name Epikuron 135F®.

As stated in the Martindale Extra Pharmacopeia, lecithin is 'a phospholipid composed of a complex mixture of acetone-
20 insoluble phosphatidyl esters (phosphatides) which consist chiefly of phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl serine, and phosphatidyl inositol, combined with various amounts of other substances such as triglycerides, fatty acids, and carbohydrates, as separated
25 from the crude vegetable oil source. The consistency of both natural grades and refined grades of lecithin may vary from plastic to fluid, depending upon the content of free fatty acid and oil, and upon the presence or absence of other diluents'.

30 In particular, the semi-solid filling medium of the invention may contain, at least one soybean lecithin fraction with an enriched phosphatidylcholine content such

as, e.g., Epikuron 135F®, commercially available from LUCAS MEYER GmbH&Co - Hamburg - Germany.

According to the present invention, the amount of the excipient is in the range of about 0.1% to about 30% (w/w),
5 preferably from about 5 to about 15% w/w of the semi-solid filling medium.

In a preferred embodiment, the present invention provides a semi-solid filling medium which comprises CPT-11, Gelucire 44/14 and a soybean lecithin with an enriched
10 phosphatidylcholine content such as, e.g., Epikuron 135F®.

The semi-solid filling medium may optionally contain a dispersing, and/or solubilizing agent, and/or a surfactant, and /or viscosity modifiers, and/or an oral absorption promoter.

15 A dispersing agent includes cellulose and its derivatives, e.g., carboxymethylcellulose and natural gums; a solubilizing/oral absorption promoter agent includes cyclodextrins, ethanol, triacetin, propylen glycol, glycerides, medium and long chain fatty acid,
20 polyoxyethylene hydrogenated or non-hydrogenated vegetable oils derivatives; a surfactant includes poloxamers, medium chain triglycerides, ethoxylated esters, polyglycerol esters, polyoxyethylene alkyl ethers, sorbitan esters, polyoxyethylene sorbitan fatty acid esters; a viscosity
25 modifier includes hydrogenated or non-hydrogenated vegetable oils, glycerol esters, polyglycerol esters and propylene glycol esters.

The semi solid filling medium according to the invention may also optionally contain chemical stabilizing-promoting
30 agents such as antioxidants and chelating agents.

The semi solid filling medium may optionally comprise one or more additional active drug substances, comprising, for example, antitumor antibiotics such as, e.g. anthracyclines;

thymidylate synthase inhibitors including, e.g.,
capecitabine; epidermal growth factor receptor inhibitors;
antimicrotubule agents including, e.g., taxanes comprising,
e.g. paclitaxel and docetaxel and vinca alkaloids;
5 angiogenesis inhibitors including, e.g. thalidomide, SU 5416
and SU 6668; chemosensitisers; cyclooxygenase-2 (COX-2)
inhibitors including, e.g., celecoxib, valdecoxib,
parecoxib and rofecoxib; aromatase inhibitors; alkylating
agents including, e.g., estramustine phosphate;
10 antimetabolites; hormonal agents including, e.g., tamoxifen;
platinum analogues including, e.g., cisplatin, carboplatin
and oxaliplatin; octreotide; glutamine and leucovorin.

A semi-solid filling medium according to the invention may
be prepared by means of conventional techniques known to one
15 of ordinary skill in the art.

Typically, a semi-solid filling medium is a dispersion or a
solution of the active ingredient in a thermosoftening hot
melt inert carrier prepared by mixing or homogenization and
filled into capsules as liquid using fluid-filling pumps and
20 allowed to solidify at ambient temperature. The major
advantage of semi-solid media is the safety during
manufacturing, being the drug dispersed/dissolved in a
liquid mass. At ambient condition such a formulation is
solid, providing better chemical stability and minimizing
25 leakage problems.

As an example, the semi-solid medium to be filled into
capsules may be prepared by adding a camptothecin derivative
to a molten homogenous mixture of a polyglycolized glyceride
and a suitable excipient such as, e.g., a lecithin. This is
30 then followed by thorough mixing of the molten mass and
capsule filling using standard techniques.

Gelatin, gelatin-PEG, starch, hydroxypropylmethylcellulose
(HPMC) or casein shell capsules can be chosen as oral dosage

forms for a semi-solid filling medium according to the invention.

The pharmaceutical composition of the invention can be administered to a mammal including a human that may need the
5 beneficial effects of a camptothecin derivative formulation described in the invention. The capsules according to this invention may therefore be used to treat a variety of different cancer types including, without limitation, human cancers of the colon, breast, lung, prostate, melanoma,
10 pancreas, liver, stomach, brain, kidney, uterus, cervix, ovaries and urinary tract.

Preferably, when the capsule comprises CPT-11, it can be used for treating a colon cancer, in particular colorectal cancer.

15 Although the examples reported in the description consider the use of CPT-11, this formulation approach may be applicable to any other camptothecin derivative.

The following examples are given with the purpose to better illustrating the invention but in no way they must be
20 considered as a limitation of the scope of the invention itself.

EXAMPLE 1

METHOD OF PREPARATION

25 For each preparation a proper quantity of the selected Gelucire® was melted at 60°C under magnetic stirring. The required amount of melted Gelucire® (5 mL) was withdrawn by means of a manual pipette (e.g. Brand-Transferpettor or the like) and added to the required quantity of CPT-11 (500 mg).
30 The drug was dispersed in the molten matrix under magnetic stirring at 60°C for two hours.

The obtained dispersion was then filled into size 0 hard gelatine capsule (0.5 mL/capsule) using a manual pipette.

The capsules manufactured as described above were tested for dissolution rate according to USP Basket method; 100 rpm; 37°C in simulated gastric fluid pH 1.2 without enzymes

RESULTS

- 5 In the following Table 1 the release profile of CPT-11 from different Gelucire® based systems are shown. The higher is the hydrophilicity of the excipient (the hydrophilicity value is given by the second figure of the identification code that is index of the Hydrophilic-Lipophilic Balance
10 (HLB) value - the higher is the number, the more hydrophilic is the excipient -) the faster is the release profile.

The results are expressed as percent of the active released from the formulation vs. the theoretical as a function of time. The composition of each formulation was basically 50
15 mg of CPT-11 dispersed in 0.5 ml of the appropriate Gelucire® per capsule.

Table 1

TIME (minutes)	% CPT-11 RELEASED (percent of the theoretical)			
	Gelucire® 44/14	Gelucire® 50/13	Gelucire® 35/10	Gelucire® 46/07
15	29.51	0.53	1.20	0.0
30	74.82	2.15	2.68	0.21
60	87.76	4.33	7.15	0.53
120	91.73	9.78	17.72	1.07
180	92.53	15.94	26.60	1.64

EXAMPLE 2

- 20 The following example shows the cases where the thickening of the semisolid matrix systems loaded with CPT-11 was experienced and where not.

METHOD OF PREPARATION

The formulations containing Gelucire® as the sole component were prepared as described in Example 1.

For each preparation containing a mixture of different
5 components, the semi-solid matrix was prepared by mixing the selected materials at 60°C under magnetic stirring for 15 minutes.

The required amount of melted semi-solid matrix (5 mL) was withdrawn by means of a manual pipette (e.g. Brand-
10 Transferpettor or the like) and added to the required quantity of CPT-11 (500 mg). The drug was carefully dispersed in the molten matrix under magnetic stirring at 60°C.

After 2, 24 and 48 hours, where it was possible, 0.5 ml
15 samples of the molten matrix were withdrawn by means of a manual pipette and filled into hard gelatine capsules.

RESULTS

The manufacturing of capsule after 2, 24 or 48 hours was impossible for some of the formulations tested (Table 2).

20 The impossibility of withdrawing of samples, due to the thickening of the mass, is a clear index of physical transformation of the semi-solid matrix and of difficulties or impossibility to manufacture any dosage form with such compositions. When the same experiment is performed on the
25 excipients *per se* (without the active), no thickening was experienced. This is the clear demonstration that this effect is due to a physical interaction between the excipients and CPT-11.

Table 2

Batch Number	SEMISOLID MATRIX BASE	WORKABILITY AT 60°C (TIME OF THE WITHDRAWAL)		
		2 HOURS	24HOURS	48HOURS
ND01645	Gelucire44/14	Y	N	-
ND01648	Gelucire44/14:Gelucire46/07 1:1 (v/v)	Y	N	-
ND01649	Gelucire50/13	Y	N	-
ND01653	Gelucire35/10	Y	N	-
ND01671	Gelucire44/14:AkolineMCM 9:1 (v/v)	Y	Y	Y
ND01672	Gelucire44/14:Epikuron135F 9:1 (v/v)	Y	Y	Y
ND01673	Gelucire44/14:Emultop 9:1 (w/w)	Y	Y	Y
ND01681	Gelucire44/14:RyloMG18 9:1 (w/w)	Y	Y	Y
ND01691	Gelucire44/14:Epikuron135F 95:5 (v/v)	Y	Y	Y
ND01692	Gelucire44/14:Epikuron135F 98:2 (v/v)	Y	Y	Y

Y = withdrawal allowed

N = withdrawal not allowed by the thickening of the mass

5 AkolineMCM = mono/diglyceride of medium chain fatty acid
(primarily caprylic and capric acids)

Emultop = soybean lecithin

RyloMG18 = glyceril monostearate

10 As shown in the above Table 2, Gelucires® cannot be used per se for formulating CPT-11, due to the evident thickening. Mixtures of Gelucires® with Akoline MCM, Epikuron 135F, Emultop and RyloMG18 do not present such thickening issue.

15 EXAMPLE 3

In the following Table 3 the dissolution rate profiles of CPT-11 from the formulation ND01671 described in Example 2, containing Gelucire® 44/14 and AkolineMCM 9:1 v/v as components of the semi-solid matrix, are shown as a function

of the manufacturing time. Samples of 0.5 ml were withdrawn from the molten mass stirred at 60°C, after 2 hours (column 'A') and 48 hours (column 'B') and partitioned in capsules. The dissolution rate tests were performed with the USP Basket method; 100 rpm; 37°C in Simulated Gastric Fluid pH 1.2 without enzymes. The data are expressed as percent of the active released from the formulation. The theoretical unit dosage strength is 50 mg CPT-11 per capsule.

The results obtained clearly show that the longer is the molten mass stirring time at 60°C before partitioning into capsules, the lower is the release profile when the capsule formulation are tested for dissolution rate.

This effect, highlighted during a control in process of the manufacturing process, can be considered predictive of what is going to happen to formulations with aging.

Table 3

Time (minutes)	Percent of CPT-11 released from the formulation	
	'A'	'B'
15	59.40	0.86
30	84.97	2.33
60	86.72	13.95
120	86.54	43.85
180	87.27	70.27
240	87.77	84.13

EXAMPLE 4

In the following Table 4 the dissolution rate profiles of CPT-11 from the formulation ND01681 described in Example 2, containing Gelucire® 44/14 and RyloMG18 9:1 w/w as components of the semi-solid matrix, are shown as a function of the manufacturing time. Samples of 0.5 ml were withdrawn

from the molten mass stirred at 60°C, after 2 hours (column 'A') and 48 hours (column 'B') and partitioned in capsules. The dissolution rate tests were performed with the USP Basket method; 100 rpm; 37°C in Simulated Gastric Fluid pH 1.2 without enzymes. The data are expressed as percent of the active released from the formulation. The theoretical unit dosage strength is 50 mg CPT-11 per capsule.

The results obtained clearly show that the longer is the molten mass stirring time at 60°C before partitioning into capsules the lower is the release profile when the capsule formulation are tested for dissolution rate.

This effect, highlighted during a control in process of the manufacturing process, can be considered predictive of what is going to happen to formulations with aging.

Table 4

Time (minutes)	Percent of CPT-11 released from the formulation	
	'A'	'B'
15	9.74	3.32
30	28.31	13.73
60	61.12	36.85
120	87.18	67.53
180	87.47	81.63
240	87.45	83.63

EXAMPLE 5

In the following Table 5 the dissolution rate profiles of CPT-11 from the formulation ND01672 described in Example 2, containing Gelucire® 44/14 and Epikuron135F 9:1 v/v as components of the semi-solid matrix, are shown as a function of the manufacturing time. Samples of 0.5 ml were withdrawn from the molten mass stirred at 60°C, after 2 hours (column 'A') and 48 hours (column 'B') and partitioned in capsules.

The dissolution rate tests were performed with the USP Basket method; 100 rpm; 37°C in Simulated Gastric Fluid pH 1.2 without enzymes. The data are expressed as percent of the active released from the formulation. The theoretical unit dosage strength is 50 mg CPT-11 per capsule.

The results obtained clearly show that the drug dissolution rate is not influenced by the stirring time of the molten mass before partitioning into capsules. In fact, the dissolution release profiles obtained from capsules manufactured both after 2 and 48 hours of stirring at 60°C are superimposable.

This effect, highlighted during a control in process of the manufacturing process, can be considered predictive of what is going to happen to formulations with aging.

Table 5

Time (minutes)	Percent of CPT-11 released from the formulation	
	'A'	'B'
15	16.01	31.86
30	54.28	64.71
60	88.07	87.72
120	91.73	89.10
180	91.98	89.16
240	92.45	89.59

EXAMPLE 6

In the following example the stability results of a formulation containing 50 mg/capsule of CPT-11 dispersed in a mixture of Gelucire® 44/14 are shown.

METHOD OF PREPARATION

Preparation of CPT-11 Bulk Dispersion

- 1) In a suitable vessel or vial, melt about 50 mL of Gelucire® 44/14 at 60°C under magnetic stirring.

- 2) Withdraw 40 mL of molten Gelucire® with a manual pipette and add it into a thermostated vessel or vial containing the pre-weighed amount of CPT-11 (4 g).
- 3) Disperse the drug in the molten matrix maintaining under stirring at 60°C for about 4 hours

Capsule filling

- 1) Withdraw 0.610 ml samples of the CPT-11 bulk dispersion by means of a manual pipette and fill the capsules. Maintain the bulk dispersion at 60°C and under constant stirring during the filling process.
- 2) Allow the filled capsules to cool at room temperature.
- 3) Package the manufactured capsules using a suitable conventional container

The capsules prepared as described above have been submitted to an accelerated stability plan and the results obtained are shown in Table 6.

Table 6

Storage Conditions	Age (Months)	Assay (mg/cps)	Total related substances (%w/w)	Dissolution (% released in 60 minutes)
Initial		52.85	0.58	101
35°C	1	53.72	0.68	54
	3	52.14	0.87	42
	6	51.27	0.86	36
40°C	1	52.55	0.79	37
75%R.H.	3	50.07	0.84	61
	6	50.22	0.88	20
Limits		45 to 55	1.50	

Legenda: R.H.: relative humidity

mg/cps: milligrams per capsule

w/w: weight/weight

As clearly depicted in Table 6 an evident decrease in the drug dissolution rate from the dosage form has been
5 experience with the CPT-11 semi-solid matrix formulation containing Gelucire® 44/14 as a carrier.

EXAMPLE 7

In the following example the stability results of a
10 formulation containing 50 mg/capsule of CPT-11 dispersed in a mixture of Gelucire® 44/14 and Epikuron135F are shown.

METHOD OF PREPARATION

Preparation of CPT-11 Bulk Dispersion

- 1) In a suitable vessel or vial, melt about 80 mL of
15 Gelucire® 44/14 at 60°C under magnetic stirring.
- 2) Withdraw 72 mL of molten Gelucire® with a manual pipette and add it into a thermostated vessel or vial
- 3) Add 8 mL, exactly measured with a manual suitable pipette, of Epikuron135F to the molten Gelucire®
- 20 4) Stir gently at 60°C till an homogeneous mixture is obtained
- 5) Add 70 mL of the Gelucire®/Epikuron molten matrix to a suitable thermostated vessel or vial containing the pre-weighed amount of CPT-11 (7 g).
- 25 6) Disperse the drug in the molten matrix maintaining under stirring at 60°C for about 4 hours

Capsule filling

- 1) Withdraw 0.610 ml samples of the CPT-11 bulk dispersion by means of a manual pipette and fill the capsules.
30 Maintain the bulk dispersion at 60°C and under constant stirring during the filling process.
- 2) Allow the filled capsules to cool at room temperature.

3) Package the manufactured capsules using a suitable conventional container

The capsules prepared as described above have been submitted to an accelerated stability plan and the results obtained
5 are shown in Table 7.

Table 7

Storage Conditions	Age (Months)	Assay (mg/cps)	Total related substances (%w/w)	Dissolution (% released in 60 minutes)
Initial		53.42	0.50	97
35°C	1	52.61	0.59	97
	3	51.23	0.60	104
	6	50.92	0.58	100
40°C 75%RH	1	53.42	0.55	92
	3	51.57	0.69	107
	6	50.14	0.73	95
Limits		45 to 55	1.50	

Legenda: R.H.: relative humidity

mg/cps: milligrams per capsule

10 w/w: weight/weight

As clearly shown in the above Table 7, no changes both in dissolution profile and in chemical strength of the formulation is highlighted when CPT-11 is formulated into a
15 gelucire/lecithin based formulation. This is in contrast with what has been shown in the previous example 6, where CPT-11 was formulated only into gelucire.

CLAIMS

1. A pharmaceutical composition suitable for oral administration which comprises a camptothecin derivative,
5 a pharmaceutically acceptable carrier matrix which is a polyglycolized glyceride, and at least one pharmaceutically acceptable excipient chosen from a lecithin, a phospholipid, a pharmaceutically acceptable oil, a polyethyleneglycol, and a saturated or unsaturated
10 mono-, di- or triglyceride.
2. A composition as defined in claim 1, wherein the camptothecin derivative is CPT-11, topotecan hydrochloride, SN-22, SN-38, 9-amino-20(S) camptothecin
15 and 9-nitro-20(S)camptothecin.
3. A composition according to claim 1 or 2, wherein the camptothecin derivative is CPT-11.
- 20 4. A composition as defined in anyone of claim 1 to 3, wherein the carrier matrix is a polyglycolized glyceride.
5. A composition according to claim 4, wherein the polyglycolized glyceride is Gelucire 44/14.
- 25 6. A composition as defined in any one of claims 1 to 5, wherein the pharmaceutically acceptable excipient is a lecithin.
- 30 7. A composition according to claim 6 wherein the lecithin is a soybean lecithin with an enriched phosphatidylcholine content.

8. A composition as defined in any one of the preceding claims which comprises CPT-11, Gelucire 44/14 and a soybean lecithin with an enriched phosphatidylcholine content.
- 5
9. A composition as defined in anyone of claims 1 to 8, which further comprises a dispersing agent, and/or a solubilizing agent, and/or a surfactant, and /or a viscosity modifier, and/or an oral absorption promoter, and/or a chemical stabilizing-promoting agent such as an antioxidant or a chelating agent.
- 10
10. An oral formulation which comprises a capsule shell and, as a filling, a composition as defined in any one of claims 1 to 9.
- 15
11. An oral formulation as defined in claim 10 for use in the treatment of a human cancer.
- 20
12. Use of a camptothecin derivative, a polyglycolized glyceride and a pharmaceutically acceptable excipient selected from a lecithin, a phospholipid, a pharmaceutically acceptable oil, a polyethyleneglycol and a saturated or unsaturated mono-, di- or tri-glyceride in the manufacture of a medicament for oral administration in the treatment of tumours.
- 25
13. Use of a lecithin, a phospholipid, a pharmaceutically acceptable oil, a polyethyleneglycol, or a saturated or unsaturated mono-, di- or triglyceride as an excipient in a pharmaceutical composition which comprises a polyglycolized glyceride and a camptothecin derivative.
- 30

14. Use of a lecithin as an excipient in a pharmaceutical composition which comprises a polyglycolized glyceride and a camptothecin derivative.
- 5 15. Use of a soybean lecithin with an enriched phosphatidylcholine content as an excipient in a pharmaceutical composition which comprises Gelucire 44/14 and CPT-11.
- 10 16. A process for producing a pharmaceutical composition as defined in claim 1, which process comprises adding an effective amount of the or each said pharmaceutically acceptable excipient to a solution or dispersion of a camptothecin derivative in the polyglycolised glyceride.
- 15 17. A process for producing a pharmaceutical composition as defined in claim 1, which process comprises dissolving or dispersing a camptothecin derivative in a molten homogenous mixture of the polyglycolized glyceride and
- 20 the or each said pharmaceutically acceptable excipient.
18. A composition as defined in claim 1, which further comprises one or more additional active drug substances, comprising, for example, antitumor antibiotics such as,
- 25 e.g. anthracyclines; thymidylate synthase inhibitors including, e.g., capecitabine; epidermal growth factor receptor inhibitors; antimicrotubule agents including, e.g., taxanes comprising, e.g. paclitaxel and docetaxel and vinca alkaloids; angiogenesis inhibitors including,
- 30 e.g. thalidomide, SU 5416 and SU 6668; chemosensitisers; cyclooxygenase-2 (COX-2) inhibitors including, e.g., celecoxib, valdecoxib, parecoxib and rofecoxib; aromatase inhibitors; alkylating agents including, e.g.,

estramustine phosphate; antimetabolites; hormonal agents including, e.g., tamoxifen; platinum analogues including, e.g., cisplatin, carboplatin and oxaliplatin; octreotide; glutamine and leucovorin.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/09647

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/47 A61K9/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 06031 A (PALEPU NAGESWARA R ;CHRISTENSEN GREGORY A (US); SMITHKLINE BEECHAM) 11 February 1999 (1999-02-11) page 2, line 17 - line 26 page 3, line 19 -page 4, last line; claims; examples ---	1-18
A	WO 96 11669 A (PHARMACIA INC) 25 April 1996 (1996-04-25) page 1, paragraph 1 page 4, last paragraph -page 5, paragraph 1 page 13, paragraph 1; claims 1-6,9-11,13; examples 1-8 --- -/--	1-18

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

11 January 2001

Date of mailing of the international search report

19/01/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Marttin, E

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/09647

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO 99 42086 A (MERCK PATENT GMBH ;SASLAWSKI OLIVIER (FR); GIET PHILIPPE (FR); HUL) 26 August 1999 (1999-08-26) page 1, line 5 - line 15 page 3, line 26 - line 35 page 7, line 12 - line 33 page 17, line 34 -page 18, line 25 page 19, line 15 - line 25; claims 1,14-16,21; examples 1,3-5 -----</p>	1-18

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/09647

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9906031 A	11-02-1999	AU 8604598 A ZA 9806877 A	22-02-1999 15-06-1999
WO 9611669 A	25-04-1996	AU 689983 B AU 4018595 A CA 2202531 A CN 1160344 A EP 0785772 A HU 77975 A IL 115099 A JP 10507454 T NO 971668 A NZ 296389 A PL 319588 A ZA 9507860 A	09-04-1998 06-05-1996 25-04-1996 24-09-1997 30-07-1997 28-01-1999 11-04-1999 21-07-1998 11-04-1997 29-06-1999 18-08-1997 21-05-1996
WO 9942086 A	26-08-1999	FR 2775188 A AU 3140899 A BR 9908121 A EP 1056445 A NO 20004190 A	27-08-1999 06-09-1999 24-10-2000 06-12-2000 20-10-2000